Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Depreciation & Amortization (CF) (2019 - 2025)

AVITA Medical's Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $700000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 71.15% year-over-year to $700000.0; the TTM value through Dec 2025 reached $2.3 million, up 108.44%, while the annual FY2025 figure was $2.3 million, 108.44% up from the prior year.
  • Depreciation & Amortization (CF) reached $700000.0 in Q4 2025 per RCEL's latest filing, up from $574000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $700000.0 in Q4 2025 to a low of -$217000.0 in Q2 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $262894.7, with a median of $187000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 163.27% in 2022, then soared 170.59% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $174000.0 in 2021, then fell by 25.29% to $130000.0 in 2022, then soared by 43.85% to $187000.0 in 2023, then surged by 118.72% to $409000.0 in 2024, then soared by 71.15% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Depreciation & Amortization (CF) are $700000.0 (Q4 2025), $574000.0 (Q3 2025), and $552000.0 (Q2 2025).